Pro-Dex (NSDQ:PDEX) said yesterday it sold its Oregon Micro Systems division for $640,000 to OMS Motion, a corporation formed by the division’s long time general manager Phil Brown. The Irvine, Calif.-based company’s OMS division designs and manufactures embedded multi-axis motion controllers to be sold to distributors or original equipment manufacturers in automation and research industries. “The […]
Pro-Dex Inc.
MRI Interventions to shutter Memphis plant
MRI Interventions (OTC:MRIC) said it plans to shutter its plant in Memphis in May and lay off all the workers there as the consolidates in Irvine, Calif.
Amniox Medical taps ex-Smith & Nephew honcho Dugan for CEO | Personnel Moves
Pro-Dex plans $3M rights offering
NxStage Medical taps Funari to replace Chambon as chairman | Personnel Moves
NxStage Medical (NSDQ:NXTM) named Robert Funari to replace Philippe Chambon as non-executive chairman after 15 years on the medical device company’s board of directors.
ResMed CEO Farrell hands corner office to his son | Personnel Moves
AtriCure prices $24M stock offering | Wall Street Beat
AtriCure (NSDQ:ATRC) priced a public offering of nearly 3.5 million shares of stock at $7.25 per share, saying it expects net proceeds of about $23.5 million.
The West Chester, Ohio-based medical device company said it granted underwriter Piper Jaffray a 30-day over-allotment option for another 521,000 shares.
CareFusion hits 52-week high on Q3 results | Earnings Roundup
CareFusion (NYSE:CFN) hit a 52-week high Friday after beating Wall Street boffins’ predictions for its 3rd-quarter earnings and raising its full-year revenue guidance.
The San Diego-based medical device maker reported profits of $31 million, or 13¢ per diluted share, on sales of $919 million during the 3 months ended March 31, a top-line gain of 9.1%.
Amgen mourns death of founder George Rathmann | Personnel Moves
Accuray dives despite beating The Street as losses gape | Earnings Roundup
Accuray (NSDQ:ARAY) shares are down today after the radiosurgery company reported surging first-quarter sales and beat Wall Street’s earnings expectations, as investors reacted to net losses of nearly six times the Q1 2011 mark.
Accuray reported losses of $26.5 million, or 38 cents per share, on sales of $100.5 million for the three months ended Sept. 30. That’s top-line growth of 163.9 percent compared with the same period last year, largely due to the massive infusion that followed ARAY’s acquisition of rival TomoTherapy earlier this year.
Accuray slips into the red in Q4, FY2011 | Earnings Roundup
Accuray Inc. (NSDQ:ARAY) may be the fish that swallowed the whale, but it might have bitten off more than it can chew judging from its fourth-quarter and fiscal 2011 results.
The Sunnyvale, Calif.-based radiosurgery device maker paid $300 million for its larger rival TomoTherapy in March. That acquisition sent ARAY into the red for both the quarter and full year.
